登录后查看消息通知
搜索
常见问题
消息
登录
首页
/
数据集
/
Individual clinical signs and calculation of clinical scores (CS) and percentage reduction of CS at each time-point.
Individual clinical signs and calculation of clinical scores (CS) and percentage reduction of CS at each time-point.
收藏
NIAID Data Ecosystem
2026-03-12 收录
临床疗效评估
临床评分系统
数据链接：
https://figshare.com/articles/dataset/Individual_clinical_signs_and_calculation_of_clinical_scores_CS_and_percentage_reduction_of_CS_at_each_time-point_/13423383
数据链接
链接失效反馈
官方服务：
问题咨询
购买咨询
在线客服
NEW
资源简介：
(XLSX)
应用场景：
创建时间：
2020-12-18
相关数据集
Comparison of baseline characteristics between responder and non-responder.
临床疗效评估
患者特征分群
Comparison of baseline characteristics between responder and non-responder.
NIAID Data Ecosystem
7
0
Variables within NEWS, qSOFA and SIRS criteria.
临床评分系统
患者风险评估
Variables within NEWS, qSOFA and SIRS criteria.
NIAID Data Ecosystem
5
0
Quality health indicators achieved over the first 12 months of observation, stratified by treatment allocation (N = 818).
临床疗效评估
医疗质量指标
Quality health indicators achieved over the first 12 months of observation, stratified by treatment allocation (N = 818).
Figshare
2022-11-02 更新
3
0
Unweighted absolute risks and number needed to treat (NNT) for events of interest after 10 years of follow-up.
临床疗效评估
乳腺癌长期随访
95% CI, 95% confidence intervals. ER, estrogen receptor. *Negative value suggests more events in extended adjuvant group (i.e. net harm).
NIAID Data Ecosystem
6
0
An Observational Study of Adjuvant Treatment With Capecitabine (Xeloda) in Combination With Oxaliplatin in Participants With Stage III Colon Cancer
结直肠癌辅助化疗
临床疗效评估
This observational study evaluates the efficacy and safety of capecitabine in combination with oxaliplatin in the adjuvant setting in participants with Stage III colon cancer. Data were collected from
NIAID Data Ecosystem
4
0
© 2023-2026 上海数据发展科技有限责任公司 版权所有
沪ICP备17003045号-15
沪公网安备31010402336585号
热门搜索
社区交流群
科研交流群
商业服务
数据资源
寻源服务
数据采集
标注服务
数据产品
代理销售
数据领域
凭证登记
数据产品
介绍推广
